305 related articles for article (PubMed ID: 33588656)
1. Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye.
Daull P; Nagano T; Gros E; Feraille L; Barabino S; Garrigue JS
Curr Eye Res; 2021 Aug; 46(8):1096-1104. PubMed ID: 33588656
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
Daull P; Barabino S; Feraille L; Kessal K; Docquier M; Parsadaniantz SM; Baudouin C; Garrigue JS
Curr Eye Res; 2019 May; 44(5):476-485. PubMed ID: 30664361
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
[TBL] [Abstract][Full Text] [Related]
5. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.
Zhu L; Zhang C; Chuck RS
Mol Vis; 2012; 18():1803-12. PubMed ID: 22815633
[TBL] [Abstract][Full Text] [Related]
6. Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model.
Liang H; Baudouin C; Daull P; Garrigue JS; Brignole-Baudouin F
Mol Vis; 2012; 18():2195-204. PubMed ID: 22919267
[TBL] [Abstract][Full Text] [Related]
7. Cevimeline-induced anti-inflammatory effect through upregulations of mucins in the ocular surface of a dry eye mouse model.
Kim CE; Kim YJ; Hwang MW; Park YJ; Yang J
Biomed Pharmacother; 2021 Jul; 139():111571. PubMed ID: 33857915
[TBL] [Abstract][Full Text] [Related]
8. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.
Kim J; Moon TK; Yoon HJ; Ji YS; Yoon KC
J Ocul Pharmacol Ther; 2021 Oct; 37(8):472-478. PubMed ID: 34449255
[No Abstract] [Full Text] [Related]
10. RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Kim CE; Kleinman HK; Sosne G; Ousler GW; Kim K; Kang S; Yang J
Sci Rep; 2018 Jul; 8(1):10500. PubMed ID: 30002412
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of topical adiponectin in a mouse model of desiccating stress-induced dry eye.
Li Z; Woo JM; Chung SW; Kwon MY; Choi JS; Oh HJ; Yoon KC
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):155-62. PubMed ID: 23211823
[TBL] [Abstract][Full Text] [Related]
12. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands.
Stern ME; Beuerman RW; Fox RI; Gao J; Mircheff AK; Pflugfelder SC
Cornea; 1998 Nov; 17(6):584-9. PubMed ID: 9820935
[TBL] [Abstract][Full Text] [Related]
13. Effect of Retinol Palmitate on Corneal and Conjunctival Mucin Gene Expression in a Rat Dry Eye Model After Injury.
Tabuchi N; Toshida H; Koike D; Odaka A; Suto C; Ohta T; Murakami A
J Ocul Pharmacol Ther; 2017; 33(1):24-33. PubMed ID: 28009531
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome.
Žiniauskaite A; Ragauskas S; Hakkarainen JJ; Rich CC; Baumgartner R; Kalesnykas G; Albers DS; Kaja S
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3088-3093. PubMed ID: 30025146
[TBL] [Abstract][Full Text] [Related]
16. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K; Stevenson OD; Mundorf TK; Reis BL
Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of retinoic acid ophthalmic emulsion in dry eye.
Selek H; Unlü N; Orhan M; Irkeç M
Eur J Ophthalmol; 2000; 10(2):121-7. PubMed ID: 10887922
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model.
Zhu L; Shen J; Zhang C; Park CY; Kohanim S; Yew M; Parker JS; Chuck RS
Mol Vis; 2009; 15():250-8. PubMed ID: 19190733
[TBL] [Abstract][Full Text] [Related]
19. Effects of silk fibroin in murine dry eye.
Kim CE; Lee JH; Yeon YK; Park CH; Yang J
Sci Rep; 2017 Mar; 7():44364. PubMed ID: 28281688
[TBL] [Abstract][Full Text] [Related]
20. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
